Which "strong buy" ratings should you follow?

Good morning, This afternoon, I would like to invite you to look at our proprietary list of 10 research houses that actually get their ratings right. If you had bought every stock the top-rated brok... Unsubscribe Good morning, This afternoon, I would like to invite you to look at our proprietary list of 10 research houses that actually get their ratings right. If you had bought every stock the top-rated broker recommended and held them for a year, your annualized ROI would be 125%. Who wouldn't want that?   This isn't a subjective list written by some random blogger. MarketBeat tracks 200,000 ratings each year and tracks how a stock performs in the 12 months that follow a recommendation. This list was created with advanced data analysis and MarketBeat's proprietary database of analyst recommendations. You'll learn which research firms' recommendations have the highest ROI. You'll learn which brokers issue the most accurate price targets. You'll also get access to the five most recent ratings from each of our top brokers. You are going to want to see this list before the market opens tomorrow. Click here to see the list now. William Bushee MarketBeat

Thank you for subscribing to MarketBeat!   We empower individual investors to make better trading decisions by providing real-time financial information and objective market research.   MarketBeat is a small business and email is a crucial tool for us to share information, news, trading ideas and financial products and services with our subscribers (that's you!).   If you have questions about your subscription, feel free to contact our U.S. based support team via email at contact@marketbeat.com or leave us a voicemail at (844) 978-6257.   If you would like to unsubscribe or change which emails you receive, you can manage your mailing preferences or unsubscribe from these emails.   © 2006-2023 American Consumer News, LLC dba MarketBeat. 326 E 8th St #105, Sioux Falls, SD 57103. United States.   Today's Bonus Content: BREAKING: Tiny biotech successfully treats blindness